Aspect Biosystems Announces Liver Tissue Collaboration with JSR

Vancouver, Canada - September 18, 2018 - Aspect Biosystems, a privately held biotechnology company focused on commercializing cutting-edge bioprinting technologies, is pleased to announce a new collaboration to develop human liver tissue with JSR Corporation, a leading materials supplier in a variety of technology driven markets. Through this collaboration, Aspect’s proprietary Lab-on-a-Printer™ 3D bioprinting platform and JSR’s advanced materials technology will be used to develop vascularized human liver lobules.  

“Joining forces with the innovative team at JSR offers a great opportunity to develop a predictive and human-relevant liver tissue platform,” said Tamer Mohamed, President and CEO of Aspect Biosystems. “This will help tackle the big problem of unforeseen liver toxicity, enable the modelling of diseases, and ultimately accelerate the development of new medicines. We are committed to forming strategic partnerships to fully unlock the potential of our bioprinting technology and we are excited to launch this new partnered liver program with JSR.”

“This collaboration with Aspect Biosystems is a key step forward in realizing the value of using human-relevant tissue models in drug development,” said Kouji Suzuki, Director of JSR-Keio University Medical and Chemical Innovation Center, JSR Corporation. “JSR is currently developing tissue engineering and biomaterials technologies and actively exploring business opportunities in this space. Aspect’s bioprinting technology is at the forefront of engineering functional tissues and we see the potential for this collaboration to deliver real impact in drug efficacy and toxicity testing.” 

About Aspect Biosystems

Aspect Biosystems is a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering. The company’s proprietary Lab-on-a-Printer™ platform technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. In addition to its internal tissue development programs,Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to create physiologically and commercially relevant tissues. These tissues are used for impactful applications in therapeutic discovery and regenerative medicine. www.aspectbiosystems.com 

About JSR Corporation

JSR Corporation is a multinational company with research-oriented organization that pursues close collaborations with leading innovators in a number of industries that are a key to the present and future welfare of human society: life sciences, synthetic rubbers, electronic materials, display and optical materials. JSR Corporation conducts its global life sciences business through its JSR Life Sciences Business Division. JSR Life Sciences provides specialized materials, products and services to the biotech industry both directly and through its subsidiaries Medical &Biological Laboratories Co. Ltd, KBI Biopharma, Inc., Selexis SA, and Crown Biosciences.

For more information about JSR Corporation, please visit www.jsr.co.jp/jsr_e/